我国宫颈癌疫苗市场分析及对策研究

Market Analysis and Countermeasures of Cervical Cancer Vaccine in China

宫颈癌Cervical cancer是最常见的妇科恶性肿瘤,是威胁女性健康的第二大恶性肿瘤。宫颈癌疫苗是预防宫颈癌发病的有效途径。2019年以前葛兰素史克(GSK)和默沙东(MSD)垄断了全球宫颈癌疫苗药物市场。虽然国内宫颈癌疫苗起步较晚,但在国内创新政策驱动下,20种疫苗已进入临床阶段,特别是由厦门万泰联合厦门大学研发的馨可宁于2020年4月获批上市,它是我国首个自主研发、全球第三个的宫颈癌疫苗。相比较欧美等发达国家,我国在宫颈癌疫苗推广力度上还有较大差距,我国9~45岁女性的HPV疫苗接种率不足0.05%。面对HPV疫苗接种覆盖率低,提出了优化HPV疫苗审评审批流程、将HPV疫苗纳入国家免疫规划、提高女性对HPV疫苗的认识等对策建议。

As the most common gynecological malignancy,cervical cancer(human papilloma virus,HPV)is the second largest threat to women’s health.Cervical cancer vaccine is an effective way to prevent cervical cancer.Glaxosmithkline(GSK)and Merck(MSD)dominated the global market for cervical cancer vaccines until 2019.Despite the late start of cervical cancer vaccines in China,20 vaccines have entered the clinical stage driven by domestic innovation policies.In particular,Cecolin,which is developed by INNOVAX and Xiamen University,was approved for market by National Drug Administration in April 2020.It is the first domestically developed cervical cancer vaccine in China and the third in the world.Compared with Europe and the United States and other developed countries,there is still a big gap in the promotion of cervical cancer vaccine in China,the HPV vaccine coverage rate of 9-45 years old women in China is less than 0.05%.In view of the low coverage rate of HPV vaccination,some countermeasures and suggestions were put forward,such as optimizing the review and approval process of HPV vaccine,including HPV vaccine into the national immunization program,and improving women’s understanding of HPV vaccine.